Pulse BiosciencesPLSE +3.27%31 EV-to-FCF is -35.34 as of Jul. 06, 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pulse Biosciences's Enterprise Value is $1,961.84 Mil.
Pulse Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-55.52 Mil. Therefore, Pulse Biosciences's EV-to-FCF for today is -35.34.
The historical rank and industry rank for Pulse Biosciences's EV-to-FCF or its related term are showing as below:
PLSE'
s EV-to-FCF Range Over the Past 10 Years
Min: -35.34 Med: -10.21 Max: -0.66
Current: -35.34
During the past 12 years, the highest EV-to-FCF of Pulse Biosciences was -0.66. The lowest was -35.34. And the median was -10.21.
PLSE's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.54
vs PLSE: -35.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pulse Biosciences's PE Ratio (TTM) for today is calculated as:
Pulse Biosciences's share price for today is $29.23.
Pulse Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pulse Biosciences EV-to-FCF Related Terms
Pulse Biosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's EV-to-FCF falls into.
Pulse Biosciences's current Enterprise Value is $1,961.84 Mil.
Pulse Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-55.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a EV-to-FCF of -35.34 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulse Biosciences and its competitors. According to the industry distribution chart, Pulse Biosciences ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Pulse Biosciences' EV-to-FCF too high?
Pulse Biosciences' current EV-to-FCF is -35.34. Based on the distribution chart, Pulse Biosciences ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' EV-to-FCF compare to LMAT and XRAY?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #999999 out of 417 companies for EV-to-FCF. This places Pulse Biosciences in the lower half of its industry. The industry median EV-to-FCF is 23.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.54, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current EV-to-FCF is -35.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current EV-to-FCF of -35.34. The current EV-to-FCF is -35.34. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current EV-to-FCF is -35.34 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
